100 related articles for article (PubMed ID: 20138251)
1. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
Loar P; Wahl H; Kshirsagar M; Gossner G; Griffith K; Liu JR
Am J Obstet Gynecol; 2010 Apr; 202(4):371.e1-8. PubMed ID: 20138251
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
3. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells.
Gossner G; Choi M; Tan L; Fogoros S; Griffith KA; Kuenker M; Liu JR
Gynecol Oncol; 2007 Apr; 105(1):23-30. PubMed ID: 17234261
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
Yang XK; Wang JD; Wang SY; Zhang YX
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
[TBL] [Abstract][Full Text] [Related]
5. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
7. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
Ji J; Zheng PS
Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
[TBL] [Abstract][Full Text] [Related]
8. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
Tang HJ; Jin X; Wang S; Yang D; Cao Y; Chen J; Gossett DR; Lin J
Gynecol Oncol; 2006 Feb; 100(2):308-17. PubMed ID: 16209885
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
10. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
11. Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines.
Lee CS; Kim YJ; Jang ER; Myung SC; Kim W
Eur J Pharmacol; 2010 Apr; 632(1-3):7-13. PubMed ID: 20096282
[TBL] [Abstract][Full Text] [Related]
12. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.
Watson JL; Greenshields A; Hill R; Hilchie A; Lee PW; Giacomantonio CA; Hoskin DW
Mol Carcinog; 2010 Jan; 49(1):13-24. PubMed ID: 19676105
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol inhibits glucose metabolism in human ovarian cancer cells.
Kueck A; Opipari AW; Griffith KA; Tan L; Choi M; Huang J; Wahl H; Liu JR
Gynecol Oncol; 2007 Dec; 107(3):450-7. PubMed ID: 17825886
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
15. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.
Egawa-Takata T; Endo H; Fujita M; Ueda Y; Miyatake T; Okuyama H; Yoshino K; Kamiura S; Enomoto T; Kimura T; Inoue M
Cancer Sci; 2010 Oct; 101(10):2171-8. PubMed ID: 20678156
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
17. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells.
Priebe A; Tan L; Wahl H; Kueck A; He G; Kwok R; Opipari A; Liu JR
Gynecol Oncol; 2011 Aug; 122(2):389-95. PubMed ID: 21570709
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
19. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
20. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
